MI Tumor Seek Hybrid
Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS) assay that provides a comprehensive molecular blueprint that saves tissue without compromising results
6-9 days
Average testing turnaround time upon specimen receipt
23,000+ genes
Simultaneously analyzed using WES + WTS
Available globally
*Excluding USA, EEA, EU, CH countries
What it is:
MI Tumor Seek Hybrid™ is a laboratory developed test (LDT) that simultaneously captures both DNA and RNA and performs next-generation sequencing (NGS).
Why it matters:
The test provides a comprehensive molecular blueprint and includes AI signatures to help confirm diagnosis and improve therapy selection.
TESTING WORKFLOW
How MI Tumor Seek Hybrid Works
Tumor Tissue Collected
A tissue sample is collected during a biopsy or surgical removal of your tumor.
DNA and RNA Sequencing Performed
Simultaneous WES and WTS delivers a more complete picture of the biomarkers driving your cancer.
Genomic Alterations Identified
Advanced bioinformatics identify clinically relevant genomic alterations and molecular signatures from DNA and RNA sequencing data.
Clinical Report Delivered
Results are delivered to the ordering physician within 6-9 days of specimen receipt, providing molecular insights to help personalize treatment based on your cancer.
Test results
Easy-to-Interpret Report to Guide Clinical Decisions
Results with Therapy Associations – Easy-to-understand biomarker-therapy associations specific to your patient.
Therapies with Potential Benefit/Lack of Benefit – Therapies with potential benefit are noted in green while those with a lack of benefit are noted in red.
Important Notes – Significant information about drug/biomarker associations and comments from Caris pathologists and molecular geneticists, if applicable.
Cancer-Type Relevant Biomarkers – Pre-defined biomarkers whose results will show regardless of presence or absence of an alteration.
Clinical Trials – Clinical trial information, including Right-In-Time Clinical Trials, can be found in the report.
Specimen Requirements
Sample and Laboratory Specifications
Specimen Type
FFPE Tumor Tissue
Minimum Input
≥25 ng DNA from extracted tumor nucleic acid
Variant Coverage
- SNVs
- InDels
- CNAs
- Genomic Signatures: MSI, TMB
Document Downloads
For international orders, email the completed
form to InternationalSupport@CarisLS.com, or
fax to 00 41 21 533 53 01.
*Excluding USA, EEA, EU, CH countries.
Next Steps
MI Tumor Seek Hybrid
